• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials
    Get the next $PFE alert in real time by email

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales.

    Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that role, she was responsible for developing and executing strategy, building and developing teams, and driving overall business performance in the rare diseases portfolio.

    Prior to that position, she held the role of Sales and Marketing Lead at Pfizer Israel from 2017 to 2019, where she oversaw national sales and marketing operations specifically for the company's cardiovascular product lines.

    Her earlier career at Pfizer Israel spanned 2004 to 2017, during which she held various sales and managerial positions. Before joining Pfizer, she worked as a sales representative at GSK Israel from 2002 to 2004.

    Educationally, Ms. Noy holds an LL.B. in Law from The Academic Centre of Law and Science in Israel, as well as a B.Sc. in Chemistry and Biology from Tel Aviv University. She also served in the Israel Defense Forces (IDF) as an optical systems instructor in the electro-optics unit.

    ParaZero Technologies believes that Ms. Noy's deep experience and leadership background are key strengths that she will bring to the role, supporting the company's efforts to expand its global commercial presence in the growing drone safety and aerospace sector.

    About ParaZero Technologies

    ParaZero Technologies Ltd. (NASDAQ:PRZO) is an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry. Founded in 2014 by aviation professionals and drone industry veterans, ParaZero is a recognized leader in advanced drone technologies, supporting commercial, industrial, and governmental operations worldwide. The company's product portfolio includes SafeAir, an autonomous parachute recovery system designed for aerial safety and regulatory compliance; DefendAir, a counter-UAS net-launching platform for protection against hostile drones in both battlefield and urban environments; and DropAir, a precision aerial delivery system. ParaZero's mission is to redefine the boundaries of aerial operations with intelligent, mission-ready systems that enhance safety, scalability, and security. For more information, visit https://parazero.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, ParaZero is using forward-looking statements when it discusses expanding its global commercial presence in the growing drone safety and aerospace sector. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed with the SEC on March 21, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. ParaZero is not responsible for the content of third-party websites.

    Investor Relations Contact:

    Michal Efraty

    Investor Relations

    michal@efraty.com



    Primary Logo

    Get the next $PFE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PFE
    $PRZO

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    3/2/2026$35.00Hold → Buy
    Argus
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Pfizer Inc.
    $PFE
    1/7/2026$25.00Neutral
    UBS
    Pfizer Inc.
    $PFE
    12/2/2025$26.00Neutral
    Citigroup
    Pfizer Inc.
    $PFE
    11/13/2025$30.00Sector Outperform
    Scotiabank
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    More analyst ratings

    $PFE
    $PRZO
    SEC Filings

    View All

    SEC Form 6-K filed by ParaZero Technologies Ltd.

    6-K - ParaZero Technologies Ltd. (0001916241) (Filer)

    6/1/26 4:01:28 PM ET
    $PRZO
    Military/Government/Technical
    Industrials

    SEC Form 6-K filed by ParaZero Technologies Ltd.

    6-K - ParaZero Technologies Ltd. (0001916241) (Filer)

    6/1/26 4:01:28 PM ET
    $PRZO
    Military/Government/Technical
    Industrials

    SEC Form 6-K filed by ParaZero Technologies Ltd.

    6-K - ParaZero Technologies Ltd. (0001916241) (Filer)

    5/29/26 8:21:06 AM ET
    $PRZO
    Military/Government/Technical
    Industrials

    $PFE
    $PRZO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Revach Moshe sold $14,740 worth of Ordinary Shares (15,731 units at $0.94), decreasing direct ownership by 19% to 67,236 units (SEC Form 4)

    4 - ParaZero Technologies Ltd. (0001916241) (Issuer)

    6/2/26 4:15:20 PM ET
    $PRZO
    Military/Government/Technical
    Industrials

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    6/1/26 7:42:34 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    5/18/26 4:39:33 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    $PRZO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $PFE
    $PRZO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $PFE
    $PRZO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $PFE
    $PRZO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:00 a.m. EDT. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Bre

    6/1/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

    DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the

    6/1/26 9:05:00 AM ET
    $LLY
    $NTHI
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ParaZero Secures First DefendAir Order from U.S.-Based Tier-1 Defense Corporation

    ParaZero CEO: "This initial order marks an important milestone for ParaZero and a significant step forward in penetrating the world's largest Counter-UAS market" Kfar Saba, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) ("ParaZero" or the "Company"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems industry, today announced that it has received its first order from a U.S.-based Tier-1 defense corporation for its DefendAir Net Pods. This order supports integration into the U.S.-based Tier-1 defense corporation's advanced autonomous defense applications. This achievement marks ParaZero

    6/1/26 8:35:00 AM ET
    $PRZO
    Military/Government/Technical
    Industrials

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    10/31/24 4:06:54 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gottlieb Scott bought $79,401 worth of shares (3,000 units at $26.47), increasing direct ownership by 50% to 9,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    12/19/23 9:31:01 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer upgraded by Argus with a new price target

    Argus upgraded Pfizer from Hold to Buy and set a new price target of $35.00

    3/2/26 8:00:47 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Pfizer with a new price target

    RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00

    2/25/26 7:53:28 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    $PRZO
    Leadership Updates

    Live Leadership Updates

    View All

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    Military UAV Sector Forecast to Surpass $40+ Billion as Modern Warfare Evolves

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Unmanned aerial vehicles (UAVs), commonly known as drones, have become a transformative technology in modern defense and military operations, reshaping strategies from reconnaissance to precision strike capabilities. Military drones offer armed forces enhanced situational awareness, reduced risk to personnel, and cost-efficient mission profiles across surveillance, target acquisition, logistics, and electronic warfare. As autonomous systems incorporating artificial intelligence and advanced sensor suites continue to mature, they are increasingly integral to networked battlefield operations and force multiplie

    2/19/26 8:30:00 AM ET
    $NOC
    $PRZO
    $UAVS
    Industrial Machinery/Components
    Industrials
    Military/Government/Technical
    Aerospace

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $PFE
    $PRZO
    Financials

    Live finance-specific insights

    View All

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:00 a.m. EDT. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Bre

    6/1/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 2:00 p.m. EDT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days.

    5/27/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

    Earnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products(1) Pipeline Momentum Builds on Positive Phase 3 and Mid-Stage Readouts Robust Late‑Stage R&D Pipeline, On Track to Start ~20 Key Pivotal Studies in 2026 Pfizer Inc. (NYSE:PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance(2). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "We're off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. Our R&D pipeline is advancing on multiple fronts – with positive Phase 3 readouts and enc

    5/5/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    $PRZO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ParaZero Technologies Ltd.

    SC 13G - ParaZero Technologies Ltd. (0001916241) (Subject)

    2/14/24 4:00:18 PM ET
    $PRZO
    Military/Government/Technical
    Industrials

    SEC Form SC 13G/A filed by Pfizer Inc. (Amendment)

    SC 13G/A - PFIZER INC (0000078003) (Subject)

    2/9/23 11:30:22 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Pfizer Inc.

    SC 13D - PFIZER INC (0000078003) (Filed by)

    7/27/22 4:42:06 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care